Recently, Etana, an Indonesian biopharmaceutical company, completed a series B financing of tens of millions of dollars, led by Yunfeng Fund. This round of financing will be mainly used for localized clinical and production of monoclonal antibody drugs (mAb) and high-end vaccine product pipelines, team capacity building and capacity expansion, etc., to accelerate the improvement of Etana’s product layout and localized production capacity in Indonesia and Southeast Asia .
Established in 2014, Etana is committed to the research and development, production and sales of high-quality, innovative and affordable biopharmaceuticals for the Indonesian and Southeast Asian markets, meeting the needs of Southeast Asian patients for high-quality medical products and treatment options. With years of deep cultivation and accumulation in the field of biopharmaceuticals, Etana has established a rich product pipeline, with therapeutic areas covering metabolic diseases, autoimmune diseases, infectious disease vaccines, tumors, etc.
Etana focuses on improving localized biopharmaceutical production capacity in Indonesia, and is building a production system for monoclonal antibodies, high-end vaccines and other biopharmaceuticals. Since 2020, Etana has successively completed the localized introduction of recombinant protein technology and mRNA technology platform, and has successively carried out local clinical and approval work.
Nathan Tirtana, founder of Etana, said, “As a leading company in the field of biopharmaceuticals in Indonesia, Etana is committed to providing high-quality, affordable and innovative biopharmaceuticals to patients in Indonesia and Southeast Asian countries to help Southeast Asian patients deal with tumors and other life-threatening diseases. We are very pleased to have the support of international investors. With the support and guidance of the Indonesian government, Etana will continue to enhance the production capacity of local biopharmaceuticals, improve the treatment level in Indonesia and Southeast Asian countries, and benefit the vast number of patients in Southeast Asia.”
media coverage
New budding entrepreneurial state in the investment world
Related events
- “Etana” completed tens of millions of US dollars in Series B financing, led by Yunfeng Fund2022-09-27
- The biological drug research and development platform “Clover” completed 304 million yuan in Series B financing2019-11-28
This article is reprinted from: https://readhub.cn/topic/8jE8Qqr2Gqu
This site is for inclusion only, and the copyright belongs to the original author.